Hepatitis B surface antigen titer is a good indicator of durable viral response after entecavir off-treatment for chronic hepatitis B
Han Ah Lee, Yeon Seok Seo, Seung Woon Park, Sang Jung Park, Tae Hyung Kim, Sang Jun Suh, Young Kul Jung, Ji Hoon Kim, Hyunggin An, Hyung Joon Yim, Jong Eun Yeon, Kwan Soo Byun, Soon Ho Um
Clin Mol Hepatol. 2016;22(3):382-389.   Published online 2016 Sep 25     DOI: https://doi.org/10.3350/cmh.2016.0047
Citations to this article as recorded by Crossref logo
Translational Strategies to Eliminate Chronic Hepatitis B in Children: Prophylaxis and Management in East Asian Countries
Ben Kang, Dae Yong Yi, Byung-Ho Choe
Frontiers in Pediatrics.2022;[Epub]     CrossRef
KASL clinical practice guidelines for management of chronic hepatitis B
Clinical and Molecular Hepatology.2022; 28(2): 276.     CrossRef
Drug Discovery Study Aimed at a Functional Cure for HBV
Takehisa Watanabe, Sanae Hayashi, Yasuhito Tanaka
Viruses.2022; 14(7): 1393.     CrossRef
Arthrospira Enhances Seroclearance in Patients with Chronic Hepatitis B Receiving Nucleos(t)ide Analogue through Modulation of TNF-α/IFN-γ Profile
Sheng-Jie Shiue, Chao-Ling Cheng, Han-Shiang Shiue, Chun-Nan Chen, Sheng-Wei Cheng, Li-Wei Wu, Ganbolor Jargalsaikhan, Tze-Sian Chan, Hsin-Yi Lin, Ming-Shun Wu
Nutrients.2022; 14(14): 2790.     CrossRef
Long‐term clinical outcome of HBeAg‐negative chronic hepatitis B patients who discontinued nucleos(t)ide analogues
Spilios Manolakopoulos, Hariklia Kranidioti, Anastasia Kourikou, Melanie‐Maria Deutsch, Christos Triantos, Chrysostomos Tsolias, Emanuel K. Manesis, Nicoletta Mathou, Alexandra Alexopoulou, Emilia Hadziyannis, George Papatheodoridis
Liver International.2021; 41(1): 48.     CrossRef
Advances in treatment and prevention of hepatitis B
Niraj James Shah, Mark M Aloysius, Neil Rohit Sharma, Kumar Pallav
World Journal of Gastrointestinal Pharmacology and Therapeutics.2021; 12(4): 56.     CrossRef
Discontinuation of nucleot(s)ide analogue therapy in HBeAg-negative chronic hepatitis B: a meta-analysis
Samuel Anthony Lachlan Hall, Sara Vogrin, Olivia Wawryk, Gareth S Burns, Kumar Visvanathan, Vijaya Sundararajan, Alexander Thompson
Gut.2021; : gutjnl-2020-323979.     CrossRef
Advances in treatment and prevention of hepatitis B
Niraj James Shah, Mark M Aloysius, Neil Rohit Sharma, Kumar Pallav
World Journal of Gastrointestinal Pharmacology and Therapeutics.2021; 12(4): 56.     CrossRef
Risks and Benefits of Discontinuation of Nucleos(t)ide Analogue Treatment: A Treatment Concept for Patients With HBeAg‐Negative Chronic Hepatitis B
Florian Bömmel, Thomas Berg
Hepatology Communications.2021; 5(10): 1632.     CrossRef
Improving the Prediction of Relapse After Nucleos(t)ide Analogue Discontinuation in Patients With Chronic Hepatitis B
Do Seon Song, Jeong Won Jang, Sun Hong Yoo, Jung Hyun Kwon, Soon Woo Nam, Si Hyun Bae, Jong Young Choi, Seung Kew Yoon
Clinical Infectious Diseases.2021; 73(4): e892.     CrossRef
Emerging Diagnostic Tools to Decide When to Discontinue Nucleos(t)ide Analogues in Chronic Hepatitis B
Margarita Papatheodoridi, George Papatheodoridis
Cells.2020; 9(2): 493.     CrossRef
The Yin and the Yang of Treatment for Chronic Hepatitis B—When to Start, When to Stop Nucleos(t)ide Analogue Therapy
Samuel Hall, Jessica Howell, Kumar Visvanathan, Alexander Thompson
Viruses.2020; 12(9): 934.     CrossRef
Comparison of clinical practice guidelines for the management of chronic hepatitis B: When to start, when to change, and when to stop
Hyung Joon Yim, Ji Hoon Kim, Jun Yong Park, Eileen L. Yoon, Hana Park, Jung Hyun Kwon, Dong Hyun Sinn, Sae Hwan Lee, Jeong-Hoon Lee, Hyun Woong Lee
Clinical and Molecular Hepatology.2020; 26(4): 411.     CrossRef
Efficacy of 104-week Telbivudine-based optimization strategy in patients with HBeAg-negative chronic hepatitis B virus infections
Weiqiang Gan, Jianguo Li, Chunlan Zhang, Xuefu Chen, Chaoshuang Lin, Zhiliang Gao
BMC Infectious Diseases.2020;[Epub]     CrossRef
Immunological biomarkers as indicators for outcome after discontinuation of nucleos(t)ide analogue therapy in patients withHBeAg‐negative chronic hepatitis B
Hariklia Kranidioti, Spilios Manolakopoulos, George Kontos, Michael S. Breen, Anastasia Kourikou, Melanie Deutsch, Maria Ester Quesada‐Del‐Bosque, Rocio T. Martinez‐Nunez, Mohammed M. Naiyer, Christopher H. Woelk, Tilman Sanchez‐Elsner, Emilia Hadziyannis
Journal of Viral Hepatitis.2019; 26(6): 697.     CrossRef
KASL clinical practice guidelines for management of chronic hepatitis B
Clinical and Molecular Hepatology.2019; 25(2): 93.     CrossRef
New Biomarkers of Chronic Hepatitis B
Lung-Yi Mak, Wai-Kay Seto, James Fung, Man-Fung Yuen
Gut and Liver.2019; 13(6): 589.     CrossRef
Stopping long-term treatment with nucleos(t)ide analogues is a favourable option for selected patients with HBeAg-negative chronic hepatitis B
Florian van Bömmel, Thomas Berg
Liver International.2018; 38: 90.     CrossRef
An expert consensus for the management of chronic hepatitis B in Asian Americans
M. J. Tong, C. Q. Pan, S.-H. B. Han, D. S.-K. Lu, S. Raman, K.-Q. Hu, J. K. Lim, H. W. Hann, A. D. Min
Alimentary Pharmacology & Therapeutics.2018; 47(8): 1181.     CrossRef